Skip to main content
. Author manuscript; available in PMC: 2020 Dec 28.
Published in final edited form as: Lupus. 2019 Aug 18;28(11):1337–1343. doi: 10.1177/0961203319869468

Figure 2.

Figure 2.

A-C. Linear regression analysis was performed for SCT and Belimumab patients to predict if there was a direct relationship between their nonmemory subset proportions and SLEDAI-2K scores. Slope was significantly different from non-zero when p < 0.05. D. Cartoon depicting changes in the nonmemory B cell pool in Belimumab vs Standard of Care (SCT) patients.